Shared Strengths: The Merck And Schering Pipelines
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.
You may also be interested in...
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Merck Halts Preladenant Development In Parkinson’s Following Phase III Failures
Company says it will not pursue regulatory filings for the adenosine-2a receptor antagonist because studies in moderate-to-severe and early-stage disease failed to show sufficient evidence of efficacy.
Antitrust Concerns Don’t Cloud Merck-Schering Deal
Merck and Schering expect limited divestments, including one of their two products in development for colorectal cancer.